NORTHVALE, N.J.--(BUSINESS WIRE)--Sept. 6, 2006--Elite Pharmaceuticals Inc. ("Elite" or the "Company") (Amex: ELI), has received approval from an Independent Review Board (IRB) to initiate a Phase II clinical trial of its abuse resistant drug product, ELI-216. An IRB approval is necessary before a clinical trial can commence.
